From magic bullets to designed multiple ligands

Drug Discovery Today

Volumn 9, Issue 15, 2004, Pages 641-651

  Morphy, Richard ^a   Kay, Corinne ^a   Rankovic, Zoran ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemical Biology; conjugate; Designed; Drug Discovery; guidelines; ligand; multiple; overlap; Pharmaceutical Science; pharmacophore; superfamily

Indexed keywords

5 HYDROXYTRYPTAMINE 2A RECEPTOR ANTAGONIST; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE D4 RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; ENKEPHALINASE INHIBITOR; FLUOXETINE; IBUPROFEN DERIVATIVE; IRBESARTAN; LIPOXYGENASE INHIBITOR; NETOGLITAZONE; NEUROLEPTIC AGENT; NORADRENALIN TRANSPORTER; OMAPATRILAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RIDOGREL; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER; THROMBIN INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHARMACEUTICAL; DRUG THERAPY, COMBINATION; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3242794178     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03163-0     Document Type: Review

References (54)

1. Graul A., et al. Omapatrilat. Drugs Future. 24:1999;269-277
2. Sorbera L.A., et al. Netoglitazone. Drugs Future. 27:2002;132-139
3. Barbey S., et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 12:2002;779-782
4. 4 dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry. 54:1997;567-572
5. Campiani G., et al. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. 47:2004;143-157
6. Jones H.M., et al. New targets for antipsychotics. Expert Rev. Neurother. 2:2002;61-68
7. Stahl S.M., et al. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry. 52:2002;1166-1174
8. Di Napoli M., Papa F. NCX-4016 NicOX. Curr. Opin. Invest. Drugs. 4:2003;1126-1139
9. Gasco A., et al. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 44:2001;3463-3468
10. Roques B.P., et al. 'Mixed Inhibitor-Prodrug' as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J. Med. Chem. 35:1992;2473-2481
11. Buijsman R.C., et al. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg. Med. Chem. Lett. 9:1999;2013-2018
12. Portoghese P.S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 44:2001;2259-2269
13. Murugesan N., et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin I and endothelin A receptor antagonists. J. Med. Chem. 45:2002;3829-3835
14. 1 receptor antagonist activity. Bioorg. Med. Chem. Lett. 7:1997;2819-2824
15. 1 receptor antagonist activity. Bioorg. Med. Chem. Lett. 7:1997;2825-2830
16. Merlos M., et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF). J. Pharmacol. Exp. Ther. 280:1997;114-121
17. Roques B.P., et al. N-[2-indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg. Med. Chem. Lett. 12:2002;2001-2005
18. Letavic M.A., et al. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-α converting enzyme inhibitors. Bioorg. Med. Chem. Lett. 13:2003;3243-3246
19. Conway J.G., et al. Inhibition of tumor necrosis factor-alpha (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. 298:2001;900-908
20. Ikeda S., et al. Design and synthesis of dual inhibitor for matrix metalloproteinase and cathepsin. Bioorg. Med. Chem. Lett. 12:2002;375-378
21. Kogen H., et al. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 11:2003;4389-4415
22. Dickinson R.P., et al. Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. Bioorg. Med. Chem. Lett. 5:1995;3017-3022
23. Fujita M., et al. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonist and TxSIs. Bioorg. Med. Chem. Lett. 12:2002;341-344
24. 1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg. Med. Chem. Lett. 12:2002;261-264
25. Walsh T.F., et al. Potent dual antagonist of endothelin and angiotensin II receptors derived from alpha-phenoxyphenylacetic acids (Part III). Bioorg. Med. Chem. Lett. 5:1995;1155-1158
26. Sternbach D., et al. Identification of a series of PPARγ/δ dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. 11:2001;2959-2962
27. Wermuth C.G. Selective optimization of side activities: another way for drug discovery. J. Med. Chem. 47:2004;1303-1314
28. 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. 11:2001;319-321
29. Weber A., et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 46:2003;550-557
30. Gallagher P.T., et al. Duloxetine (Cymbaltaô), as dual inhibitor of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett. 13:2003;4477-4480
31. 4 receptor antagonists. Part 2. Asymmetric synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 12:2002;3111-3115
32. 3 receptor ligands with combined inhibitory histamine N-methyl transferase activity. J. Med. Chem. 45:2002;1128-1141
33. 2- adrenoreceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues. J. Med. Chem. 41:1998;4915-4917
34. 2 and gastrin receptor antagonists. Bioorg. Med. Chem. Lett. 6:1996;1421-1426
35. Zhang H-C., et al. Macrocyclic bisindolemaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 13:2003;3049-3053
36. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25
37. Veber D.F., et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2002;2615-2623
38. Oprea T.I., et al. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41:2001;1308-1315
39. 2 binding activities of a series of diacyl-substituted 2-arylpiperazines. Bioorg. Med. Chem. Lett. 12:2002;3161-3165
40. 2 receptor dual antagonist. Chem. Pharm. Bull. (Tokyo). 50:2002;941-959
41. Bamigbade T.A., et al. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin efflux and uptake. Br. J. Anaesth. 79:1997;352-356
42. Ksander G.M., et al. Dual angiotensin converting enzyme/thromboxane synthase inhibitors. J. Med. Chem. 37:1994;1823-1832
43. 2 synthase inhibitory activities. Chem. Pharm. Bull. (Tokyo). 44:1996;1510-1520
44. Gengo P.J., et al. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5- dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. Mixed opioid agonist with potent antinociceptive activity. J. Pharmacol. Exp. Ther. 307:2003;1221-1226
45. Roques B-P., et al. Toward an optimal joint recognition of the S1′ subsites of ECE-1, ACE, and NEP. J. Med. Chem. 45:2002;1477-1486
46. Martin F.M., et al. Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression. Bioorg. Med. Chem. Lett. 13:2003;3277-3280
47. Reichard G.A., et al. The design and synthesis of novel NK1/NK2 dual antagonists. Bioorg. Med. Chem. Lett. 10:2000;2329-2332
48. B receptor antagonists. Can. J. Physiol. Pharmacol. 80:2002;464-469
49. Adams A.D., et al. Amphipathic 3-phenyl-7-propylbenzisoxazoles; human PPARγ,δ,α agonists. Bioorg. Med. Chem. Lett. 13:2003;931-935
50. Ananthan S., et al. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido-and pyrimidomorphinans. J. Med. Chem. 42:1999;3527-3538
51. Sauerberg P., et al. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem. 46:2003;4883-4894
52. Jeng A.Y., et al. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase. Clin. Sci. 103:2002;985-1015
53. De Lombaert S., et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphomethyl and N-carboxyalkyl dipeptides. Bioorg. Med. Chem. Lett. 22:1994;2715-2720
54. Borisy A., et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7977-7982